Vanguard Group’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,765,031
| Closed | -$8.67M | – | 4699 |
|
|
2021
Q3 | $8.67M | Buy |
1,765,031
+13,211
| +0.8% | +$64.2K | ﹤0.01% | 3333 |
|
|
2021
Q2 | $9.25M | Buy |
1,751,820
+34,336
| +2% | +$178K | ﹤0.01% | 3248 |
|
|
2021
Q1 | $8.24M | Buy |
1,717,484
+743,872
| +76% | +$3.88M | ﹤0.01% | 3257 |
|
|
2020
Q4 | $4.22M | Buy |
973,612
+42,470
| +5% | +$182K | ﹤0.01% | 3435 |
|
|
2020
Q3 | $3.84M | Hold |
931,142
| – | – | ﹤0.01% | 3281 |
|
|
2020
Q2 | $2.38M | Sell |
931,142
-48,286
| -5% | -$142K | ﹤0.01% | 3383 |
|
|
2020
Q1 | $2.83M | Buy |
979,428
+38,599
| +4% | +$173K | ﹤0.01% | 3199 |
|
|
2019
Q4 | $3.57M | Sell |
940,829
-25,895
| -3% | -$124K | ﹤0.01% | 3280 |
|
|
2019
Q3 | $4.95M | Sell |
966,724
-64,240
| -6% | -$397K | ﹤0.01% | 3141 |
|
|
2019
Q2 | $6.39M | Sell |
1,030,964
-248,047
| -19% | -$1.43M | ﹤0.01% | 3080 |
|
|
2019
Q1 | $9.09M | Buy |
1,279,011
+245,474
| +24% | +$2.21M | ﹤0.01% | 2877 |
|
|
2018
Q4 | $8.83M | Buy |
1,033,537
+25,089
| +2% | +$326K | ﹤0.01% | 2824 |
|
|
2018
Q3 | $20.2M | Buy |
1,008,448
+18,879
| +2% | +$443K | ﹤0.01% | 2574 |
|
|
2018
Q2 | $25.6M | Buy |
989,569
+53,064
| +6% | +$1.47M | ﹤0.01% | 2459 |
|
|
2018
Q1 | $22.4M | Buy |
936,505
+210,463
| +29% | +$6.64M | ﹤0.01% | 2454 |
|
|
2017
Q4 | $24.6M | Buy |
726,042
+18,672
| +3% | +$521K | ﹤0.01% | 2407 |
|
|
2017
Q3 | $15M | Sell |
707,370
-37,867
| -5% | -$694K | ﹤0.01% | 2621 |
|
|
2017
Q2 | $13M | Buy |
745,237
+28,818
| +4% | +$477K | ﹤0.01% | 2648 |
|
|
2017
Q1 | $12.5M | Buy |
716,419
+66,825
| +10% | +$1.14M | ﹤0.01% | 2660 |
|
|
2016
Q4 | $11M | Buy |
649,594
+25,756
| +4% | +$398K | ﹤0.01% | 2703 |
|
|
2016
Q3 | $10.2M | Buy |
623,838
+5,056
| +0.8% | +$76.9K | ﹤0.01% | 2673 |
|
|
2016
Q2 | $9.37M | Buy |
618,782
+120,912
| +24% | +$1.99M | ﹤0.01% | 2681 |
|
|
2016
Q1 | $7.2M | Buy |
497,870
+193,176
| +63% | +$3.25M | ﹤0.01% | 2784 |
|
|
2015
Q4 | $8.63M | Buy |
304,694
+92,151
| +43% | +$1.55M | ﹤0.01% | 2722 |
|
|
2015
Q3 | $3.56M | Buy |
212,543
+45,801
| +27% | +$1.04M | ﹤0.01% | 3124 |
|
|
2015
Q2 | $4.37M | Buy |
166,742
+17,581
| +12% | +$342K | ﹤0.01% | 3074 |
|
|
2015
Q1 | $2.61M | Buy |
149,161
+49,884
| +50% | +$855K | ﹤0.01% | 3297 |
|
|
2014
Q4 | $1.72M | Buy |
99,277
+60,857
| +158% | +$923K | ﹤0.01% | 3339 |
|
|
2014
Q3 | $716K | Buy |
38,420
+21,996
| +134% | +$378K | ﹤0.01% | 3605 |
|
|
2014
Q2 | $300K | Buy |
+16,424
| New | +$294K | ﹤0.01% | 3785 |
|
Vanguard Group's ADMS Position: Q4 2021 in Review
Vanguard Group sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 1,765,031 shares — an estimated $8.67M sold.
Vanguard Group first reported a position in ADMS in Q2 2014 and held it in 30 quarters. The position peaked at $25.6M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Vanguard Group reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Vanguard Group sold 1,765,031 Adamas Pharmaceuticals shares in Q4 2021, an estimated $8.67M.
- Vanguard Group first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 30 quarters.
- Vanguard Group's Adamas Pharmaceuticals position peaked at $25.6M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Vanguard Group's 13F filing for Q4 2021, filed 14 Feb 2022.